Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PETCT Scan with Tissue Biomarkers
Joint Authors
Foca, Flavia
Martinelli, Giovanni
Liverani, Chiara
Bongiovanni, Alberto
Mercatali, Laura
Pieri, Federica
De Vita, Alessandro
Spadazzi, Chiara
Miserocchi, Giacomo
Recine, Federica
Riva, Nada
Nicolini, Silvia
Severi, Stefano
Ibrahim, Toni
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-12-02
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
There is a growing need for more accurate biomarkers to facilitate the diagnosis and prognosis of patients with grade (G) 3 neuroendocrine carcinomas (NECs).
In particular, the discrimination between well-differentiated neuroendocrine carcinomas (WD-NECs) and poorly differentiated neuroendocrine carcinomas (PD-NECs) is still an unmet need.
We previously showed that 68Gallium-(68Ga-) PET/CT positivity is a prognostic factor in patients with gastroenteropancreatic (GEP) G3 NECs, correlating with a better outcome in terms of overall survival.
Here, we hypothesize that 68Ga-PET/CT could help to discriminate between WD-NECs and PD-NECs, adding complementary information to that obtained from morphologic and biologic factors.
A retrospective, single-institution study was performed on 11 patients with histologically confirmed, measurable G3 large- or small-cell GEP-NECs according to the 2017 WHO classification.
The staging procedures included a 68Ga-PET/CT scan.
Results of 68Ga-PET/CT were correlated in univariate analysis with loss of tissue immunohistochemical expression of DAXX/ATRX or RB1 frequently associated with WD-NECs or PD-NECs, respectively.
None of the patients with positive 68Ga-PET/CT showed loss of RB1 expression, whereas among those (n=6) with negative 68Ga-PET/CT, 4 showed loss of expression.
A trend towards a correlation between loss of RB1 expression and negative 68Ga-PET/CT was observed.
Our preliminary data support the hypothesis that PD-NECs carrying RB1 mutation and loss of its expression may be associated with negative 68Ga-PET/CT.
If confirmed in a larger clinical trial, 68Ga-PET/CT would help in the stratification of G3 NECs.
American Psychological Association (APA)
Liverani, Chiara& Bongiovanni, Alberto& Mercatali, Laura& Foca, Flavia& Pieri, Federica& De Vita, Alessandro…[et al.]. 2018. Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PETCT Scan with Tissue Biomarkers. Disease Markers،Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1153550
Modern Language Association (MLA)
Liverani, Chiara…[et al.]. Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PETCT Scan with Tissue Biomarkers. Disease Markers No. 2018 (2018), pp.1-8.
https://search.emarefa.net/detail/BIM-1153550
American Medical Association (AMA)
Liverani, Chiara& Bongiovanni, Alberto& Mercatali, Laura& Foca, Flavia& Pieri, Federica& De Vita, Alessandro…[et al.]. Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PETCT Scan with Tissue Biomarkers. Disease Markers. 2018. Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1153550
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1153550